← Eichor
Condition: Non Segmental Vitiligo Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Segmental Vitiligo

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
Phase 4 · 1 location(s) · Khyber Teaching Hospital · NCT06991972Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers A
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07554222A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
Phase 1 · 2 location(s) · CAGE Bio Inc. · NCT07357870A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase 2 · 35 location(s) · Eli Lilly and Company · NCT07533019A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo
Phase N/A · 116 location(s) · AbbVie · NCT07136467A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Effi
Phase 2 · 1 location(s) · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · NCT07712523Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Phase 2 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT07172347Study of D-2570 in Subjects With Non-Segmental Vitiligo
Phase 2 · 1 location(s) · InventisBio Co., Ltd · NCT07625891A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07251595An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patien
Phase 2 · 1 location(s) · Derm Texas, PLLC · NCT07105254A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase 2 · 52 location(s) · Novartis Pharmaceuticals · NCT07431177A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
Phase 1 · 6 location(s) · Forte Biosciences, Inc. · NCT06905873Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
Phase 2 · 6 location(s) · Elixiron Immunotherapeutics (Hong Kong) Ltd. · NCT07223229ICP-332 in Subjects With Non-segmental Vitiligo
Phase 2/Phase 3 · 45 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT07047612Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Phase 2/Phase 3 · 1 location(s) · Hospital Authority, Hong Kong · NCT06719024
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.